Trial · NCT00082173

Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

NCT00082173, Phase 2, Completed, Johns Hopkins University; results first posted 2013-05-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis. Trials, record NCT00082173. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00082173

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
NCT number: NCT00082173
Status: Completed
Phases: Phase 2
Enrollment: 170 participants, actual
Lead sponsor: Johns Hopkins University
Conditions: Tuberculosis
Interventions: Moxifloxacin
First posted: 2004-05-04
Last updated: 2013-05-22
Results first posted: 2013-05-22

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Patients With Sterile Sputum Cultures	8 weeks	Proportion of patients with sterile sputum cultures
Secondary	Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	8 weeks	Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Patients With Sterile Sputum Cultures	8 weeks	Proportion of patients with sterile sputum cultures at week 8	Participants	NUMBER
SECONDARY	Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	8 weeks	DAIDS Table of Adverse Events	Participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Proportion of Patients With Sterile Sputum Cultures	Experimental Arm	59	Participants
Proportion of Patients With Sterile Sputum Cultures	Control Arm	45	Participants
Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	Experimental Arm	0	Participants
Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	Control Arm	0	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Experimental Arm	74
Overall Study	STARTED	Control Arm	72
Overall Study	COMPLETED	Experimental Arm	64
Overall Study	COMPLETED	Control Arm	61
Overall Study	NOT COMPLETED	Experimental Arm	10
Overall Study	NOT COMPLETED	Control Arm	11

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Hospitalization	General disorders	Experimental Arm	3	74	4
serious	Hospitalization	General disorders	Control Arm	3	72	3
serious	Death	Cardiac disorders	Experimental Arm	3	74	3
serious	Death	Cardiac disorders	Control Arm	5	72	5
serious	Grade 4 event	Renal and urinary disorders	Experimental Arm	1	74	1
serious	Grade 4 event	Renal and urinary disorders	Control Arm	0	72	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Experimental Arm
Total, all-cause mortality	Control Arm
Total, other adverse events	Experimental Arm	0	74
Total, other adverse events	Control Arm	0	72
Total, serious adverse events	Experimental Arm	6	74
Total, serious adverse events	Control Arm	6	72

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19345831	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Experimental Arm vs Control Arm: Proportion of Patients With Sterile Sputum Cultures	Trial comparisons
Experimental Arm vs Control Arm: Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	Trial comparisons
Experimental Arm vs Control Arm: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00082173

GET https://conductscience.org/api/trials/v1/NCT00082173/registered

API reference For AI assistants